From: <Salvato da Windows Internet Explorer 8>
Subject: Alla ricerca del virus HIV
Date: Tue, 27 Apr 2010 23:01:55 +0200
MIME-Version: 1.0
Content-Type: multipart/related;
	type="text/html";
	boundary="----=_NextPart_000_0000_01CAE65D.A1CA30D0"
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.5579

This is a multi-part message in MIME format.

------=_NextPart_000_0000_01CAE65D.A1CA30D0
Content-Type: text/html;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.cesil.com/0898/itfrah08.htm

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD><TITLE>Alla ricerca del virus HIV</TITLE>
<META content=3D"text/html; charset=3Diso-8859-1" =
http-equiv=3DContent-Type>
<META name=3DAuthor content=3D"Fabio Franchi">
<META name=3DGENERATOR content=3D"MSHTML 8.00.6001.18904">
<META name=3DClassification content=3Dmedicina>
<META name=3DKeyWords content=3D"hiv, HIV, test hiv,">
<META name=3DDescription=20
content=3D"Analisi del valore dei test utilizzati per l'infezione da =
HIV"></HEAD>
<BODY aLink=3D#ffff00 link=3D#cc0000 bgColor=3D#ffffff text=3D#000000 =
vLink=3D#993300><IMG=20
align=3DABSCENTER src=3D"http://www.cesil.com/0898/migltin1.gif" =
width=3D120=20
height=3D109><FONT color=3D#ffffff>.........</FONT>&nbsp;<IMG =
align=3DABSCENTER=20
src=3D"http://www.cesil.com/0898/tosctin2.gif" width=3D550 height=3D20>=20
<CENTER>
<TABLE border=3D0 cellSpacing=3D0 cellPadding=3D0 width=3D600 cols=3D1>
  <TBODY>
  <TR>
    <TD vAlign=3Dcenter align=3Dmiddle>
      <DIV align=3Dright><IMG align=3DABSCENTER=20
      src=3D"http://www.cesil.com/0898/frahtes1.jpg" width=3D151=20
  height=3D39></DIV></TD></TR>
  <TR>
    <TD><IMG src=3D"http://www.cesil.com/0898/frahtes2.jpg" width=3D600=20
    height=3D141></TD></TR></TBODY></TABLE></CENTER>
<CENTER>&nbsp;<B><I><FONT face=3DArial,Helvetica><FONT =
color=3D#000000><FONT=20
size=3D-1>Fabio Franchi</FONT></FONT></FONT></I></B></CENTER>
<CENTER>
<TABLE border=3D0 cellSpacing=3D0 cellPadding=3D0 width=3D600=20
background=3Dhttp://www.cesil.com/0898/ficasfon.jpg cols=3D1>
  <TBODY>
  <TR>
    <TD>
      <CENTER><FONT face=3DArial,Helvetica><FONT color=3D#ffffff><FONT=20
      size=3D-1>Abstract&nbsp;<A=20
      href=3D"http://www.cesil.com/0898/iafrah08.htm"><IMG border=3D0=20
      align=3DABSCENTER src=3D"http://www.cesil.com/0898/ficapalb.jpg" =
width=3D15=20
      height=3D15></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=20
      Curriculum&nbsp;<A =
href=3D"http://www.cesil.com/0898/cufrah08.htm"><IMG=20
      border=3D0 align=3DABSCENTER =
src=3D"http://www.cesil.com/0898/ficapalb.jpg"=20
      width=3D15 =
height=3D15></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=20
      Bibliografia&nbsp;<A =
href=3D"http://www.cesil.com/0898/bifrah08.htm"><IMG=20
      border=3D0 align=3DABSCENTER =
src=3D"http://www.cesil.com/0898/ficapalb.jpg"=20
      width=3D15=20
height=3D15></A></FONT></FONT></FONT>&nbsp;</CENTER></TD></TR></TBODY></T=
ABLE></CENTER><A=20
href=3D"http://www.cesil.com/0898/enfrah08.htm">&nbsp;<A=20
href=3D"http://www.cesil.com/0898/enfrah08.htm"><IMG=20
src=3D"http://www.cesil.com/0898/usa.gif" width=3D55 =
height=3D28></A></A>=20
<CENTER>
<TABLE border=3D0 cellSpacing=3D0 cellPadding=3D7 width=3D750 cols=3D2>
  <TBODY>
  <TR>
    <TD vAlign=3Dtop align=3Dleft><B><I><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#3366ff><FONT size=3D-1>Compito del ricercatore =E8 =
cercare di=20
      falsificare quante pi=F9 teorie =E8=20
      possibile.</FONT></FONT></FONT></I></B>&nbsp;=20
      <DIV align=3Dright><FONT face=3DArial,Helvetica><FONT=20
      size=3D-1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <B>Karl=20
      Popper</B></FONT></FONT></DIV><B><I><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#3366ff><FONT size=3D-1>C'=E8 forse un pericolo nella =
biologia=20
      molecolare, ovvero che l'accumulo di dati si spinger=E0 cos=EC =
oltre alla sua=20
      assimilazione&nbsp; in una struttura concettuale, che i dati =
risulteranno=20
      infine d'impaccio? Parte della preoccupazione =E8 che =
l'eccitamento della=20
      caccia lascia poco spazio alla riflessione. E ci sono fondi per =
produrre=20
      dati, ma a stento per fermarsi in=20
      meditazione.</FONT></FONT></FONT></I></B>&nbsp;=20
      <DIV align=3Dright><B><FONT face=3DArial,Helvetica><FONT =
size=3D-1><FONT=20
      color=3D#3366ff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; =
</FONT><FONT=20
      color=3D#000000>John Maddox =
(1)</FONT></FONT></FONT></B></DIV><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Secondo la teoria=20
      infettiva dell=92AIDS, l=92infezione da HIV =E8 attiva fin dalle =
prime fasi e=20
      molto difficilmente pu=F2 essere eliminata dall=92organismo nel =
corso degli=20
      anni. La sua presenza =E8 segnalata da appositi test. Quelli =
attualmente a=20
      disposizione sono fondamentali non solamente per la diagnosi , ma =
vengono=20
      utilizzati come elementi indicativi ai fini prognostici e=20
      terapeutici.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Poich=E9 la scienza=20
      per definizione =E8 aperta ad ogni controllo ed ogni sua =
affermazione deve=20
      poter essere dimostrata in base a regole logiche, il presente =
studio si=20
      pone l=92obiettivo di verificare se vi sia corrispondenza tra i =
diversi=20
      =93test per l=92AIDS=94 ed il significato a loro attribuito. =
Verranno esaminati=20
      i principali: quelli anticorpali (ELISA e Western Blot e p24),=20
      l=92identificazione del virus tramite la coltura, =
l=92identificazione degli=20
      acidi nucleici, la sua caratterizzazione genica, le metodiche=20
      d=92isolamento, le fotografie del =
virus.</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Verr=E0=20
      analizzato e criticato il procedimento seguito attualmente, come=20
      presentato in testi specialistici aggiornati, tra questi =93AIDS, =
Biology,=20
      Diagnosis, Treatment and Prevention=94 edito nel 1997, di cui un =
autore =E8 A.=20
      Fauci, ex direttore del National Institute of=20
      Health.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>Ci siamo posti in altre parole =
l=92obiettivo di=20
      rispondere alla domanda cruciale come l=92avrebbe formulata il =
grande=20
      clinico e studioso di metodologia della scienza&nbsp; prof. =
Augusto Murri:=20
      =93Perch=E9 devo io credere che il significato dei test =
dell=92AIDS corrisponda=20
      a un=92infezione con il virus HIV?=94 Egli considerava =
indispensabile avere,=20
      nella vita come nella professione, un=92abitudine, quella di =
criticare prima=20
      di accettare una informazione.</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>ANALISI=20
      DEI TEST ANTICORPALI</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>I =
test anticorpali=20
      esaminati saranno l=92ELISA, il Western Blot, il test di cattura=20
      dell=92antigene p24.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT=20
      =
size=3D-1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT></FONT>&nbsp; =

      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT=20
      =
size=3D-1>ELISA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbs=
p;&nbsp;=20
      (fig. 1)</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>In Italia,=20
      per identificare l=92infezione da HIV viene in prima istanza =
utilizzato un=20
      test di screening (ELISA), =93dotato di buona sensibilit=E0 =
(vicino al 99%) e=20
      minore specificit=E0, stimata attorno al 90-95% nel=20
      1988=94.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Queste percentuali=20
      non debbono per=F2 trarre in inganno, infatti il valore predittivo =
del test=20
      varia a seconda della prevalenza dell=92infezione in una =
determinata=20
      popolazione. Secondo un=92ipotesi formulata dalla Commissione =
Nazionale AIDS=20
      nel 1988 , in caso di screening della popolazione carceraria =
italiana, di=20
      fronte a 6.902 veripositivi si sarebbero avuti 1.751 falsi =
positivi;=20
      invece, nel caso dei donatori di sangue, di fronte a 198 veri =
positivi,=20
      ben 99.990 sarebbero stati i falsi positivi (ben 505 volte di=20
      pi=F9!).</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>Nel libro gi=E0 citato =93AIDS=94 =
, gli autori=20
      sostengono che i progressivi perfezionamenti del test hanno =
portato la sua=20
      sensibilit=E0 al 95% e la specificit=E0 al 99,8% in popolazioni ad =
alto=20
      rischio,valori che non si discostano di molto dai precedenti. =
Viene per=F2=20
      ammesso che =93il valore predittivo positivo pu=F2 fluttuare =
grandemente in=20
      dipendenza della popolazione studiata=94. In realt=E0 cos=EC =E8=20
      avvenuto.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Stando ad=20
      informazioni pubblicate sull=92autorevole rivista medica inglese =
The Lancet,=20
      nel 1990, in Russia vennero fatti 20,2 milioni di test ELISA, di =
cui=20
      20.000 risultarono positivi, ma solo 112 vennero confermati con il =
WB; nel=20
      1991, su 30 milioni di test ELISA, ben 30.000 risultarono =
positivi, ma di=20
      questi solo 66 risultarono confermati dal Western Blot, cio=E8 una =

      percentuale minima (0,002%).</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>=93Dunque il test=20
      ELISA essendo stato disegnato per ottimizzare la sensibilit=E0 a =
spese della=20
      specificit=E0, non dovrebbe essere usato da solo per la diagnosi =
di=20
      infezione da HIV-1 senza un test di conferma=94, sebbene in alcune =
nazioni=20
      sia usato da solo.</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Il test=20
      Western Blot&nbsp; (fig. 2)</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Il Western=20
      Blot (WB) viene comunemente usato come un test di conferma =
dell=92infezione=20
      da HIV; la combinazione dell=92ELISA e del WB vanta ufficialmente =
=93un valore=20
      predittivo positivo maggiore del 99% per popolazioni a basso =
rischio e ad=20
      alto rischio=94.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Tuttavia neanche il=20
      WB appare cos=EC specifico come sostenuto se vengono analizzati =
alcuni dati=20
      a disposizione.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>a) =
Viene=20
      riconosciuto persino da fonti ufficiali che =93=E8 stato molto =
difficile&nbsp;=20
      codificare la definizione su ci=F2 che dovrebbe essere considerato =
un=20
      Western Blot positivo, a causa di discreti=20
      disaccordi=94.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Fino =
al 1993, negli=20
      Stati Uniti vi erano ben 5 criteri ufficiali, e solo uno (indicato =
nel kit=20
      diagnostico della Du Pont) era stato approvato dalla FDA (Food and =
Drug=20
      Administration). Questo era il pi=F9 restrittivo ed era usato da =
pochi=20
      laboratori.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Se =
fosse stato=20
      usato unicamente questo criterio, ben il 50% dei sieropositivi =
negli Stati=20
      Uniti sarebbero stati considerati come non=20
      infetti!&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>In =
Italia, in una=20
      pubblicazione del Ministero della Sanit=E0 rivolta ai medici di =
famiglia ,=20
      veniva negato che una questione del genere potesse costituire un =
problema.=20
      Al proposito si affermava: =93nella grande maggioranza dei=20
      casi,indipendentemente dal criterio utilizzato, il test risulta=20
      correttamente classificato positivo quando l=92individuo =E8 =
infetto=94. Il=20
      fatto che i risultati potevano essere ben diversi non veniva =
neppure=20
      menzionato.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>A =
tale situazione=20
      il rimedio =E8 stato trovato semplicemente uniformando i diversi =
criteri=20
      senza riconsiderare il passato e senza chiarire i motivi =
scientifici per=20
      cui cos=EC si =E8 optato.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>"I =
CDC hanno in un=20
      secondo tempo identificato i propri con quelli del ASTPHLD e nel =
1993 la=20
      Croce Rossa statunitense si =E8 adeguata adottando le =
raccomandazioni del=20
      ASTPHLD/CDC=94. =93Secondo l=92ente americano ASTPHLD, un =
risultato positivo=20
      deve presentare almeno due delle tre bande maggiori di significato =

      diagnostico (anti-gp41, anti-gp120/160,=20
      anti-p24)=94.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>b) La =
lettura del=20
      WB =E8 visiva ed =E8 soggetta perci=F2 ad interpretazione da parte =

      dell=92operatore, un fattore di variabilit=E0 non trascurabile. =
=93La sua=20
      tecnica (ndr: del Western Blot) non =E8 stata standardizzata, =
l=92importanza e=20
      le conseguenze delle variazioni verificatesi nei laboratori non =
sono=20
      ancora state misurate. I suoi risultati richiedono d=92essere =
interpretati;=20
      i criteri per queste interpretazioni variano non solo da =
laboratorio a=20
      laboratorio, ma anche di mese in =
mese=94.</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Il=20
      Consorzio statunitense per la Standardizzazione della Sierologia=20
      Retrovirale (CRSS) ha effettuato un controllo di qualit=E0 =
inviando 19 quote=20
      dello stesso siero a 19 laboratori di riferimento ed il confronto =
dei=20
      risultati ha dimostrato una strabiliante differenza del numero di =
bande e=20
      della loro intensit=E0 nelle diverse =93striscie=94 (fig.=20
      3).</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>Le preparazioni antigeniche non =
sono=20
      purificate.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>=93La =
presenza di=20
      bande in posizioni non corrispondenti a noti antigeni virali =E8 =
un=20
      ritrovamento piuttosto comune e si presume sia la=20
      =
conse&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;=20
      guenza di contaminanti nella preparazione ...=94. =93Il peso =
molecolare di=20
      queste bande aberranti pu=F2 variare da ditta a ditta&nbsp; o =
persino da=20
      lotto a lotto della medesima ditta=20
      produttrice=94.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Ecco =
il commento di=20
      Zolla-Pazner nel 1989: =93Confusione sulla=20
      =
identi&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;=20
      ficazione di queste bande (n.d.r.: i risultati del test Western=20
      =
Blot)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; =
=E8=20
      risultata in conclusioni scorrette negli studi sperimentali. [...] =

      potrebbe essere necessaria la reinterpretazione dei risultati =
gi=E0=20
      pubblicati=94.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Questa auspicata=20
      reinterpretazione non =E8 avvenuta fino al momento attuale (marzo=20
      1998).</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>d) Bande considerate =
=93specifiche=94 non indicano=20
      in molti casi un=92infezione da HIV. Seguono alcuni=20
      esempi.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>- Pur utilizzando i criteri pi=F9 =
restrittivi,=20
      Lundberg osserv=F2 che ben il 10% dei sieri di controllo, che =
includevano=20
      campioni di sangue dalle banche del sangue, avevano un WB=20
      positivo.</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>- In uno=20
      studio, si rilevava che dal 2 al 49% dei pazienti testati potevano =
avere=20
      una reattivit=E0 al WB (WB indeterminato), pi=F9 frequentemente =
causata da=20
      anticorpi cross-reagenti.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>- =
Anche una=20
      semplice vaccinazione anti-influenzale pu=F2 rendere positivo il=20
      risultato.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>- Anche la trasfusione del proprio =
sangue=20
      irradiato produce gli stessi anticorpi.</FONT></FONT></FONT>&nbsp; =

      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>- Tra gli=20
      omosessuali o bisessuali che risultano negativi per l=92ELISA e la =
PCR,=20
      20%-30% possono avere una o pi=F9 bande presenti sul Western=20
      Blot.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>- Dati ancora pi=F9 sconcertanti =
riguardano uno=20
      studio effettuato su dei cani e pubblicato nel 1990. Scrivendo su =
Cancer=20
      Research, Strandstrom e colleghi riportarono che 72 su 144 (50%) =
campioni=20
      di sangue canino ottenuti dall' Ospedale Veterinario =
dell=92Universit=E0 di=20
      California, e testati con il Western Blot reagivano con una o =
pi=F9 proteine=20
      ricombinanti dell=92HIV [gp120--21.5%, gp41--23%, p31--22%,=20
      p24--43%]=93.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Poich=E9 gli Autori=20
      considerano i cani non infetti con l=92HIV, si deve concludere che =
questi=20
      dati sono una ulteriore prova della frequente cross reattivit=E0 =
anticorpale=20
      con molte =93proteine diverse da quelle=20
      dell=92HIV=94.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>E' =
importante, a=20
      questo punto, introdurre alcune =
considerazioni.</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Il fatto=20
      che le bande siano definite non specifiche se ritrovate =
singolarmente, ma=20
      specifiche per il virus se presenti in numero di due o pi=F9 di =
due, appare=20
      rifarsi non a considerazioni di ordine biologico, ma ad una =
convenzione,=20
      ad un accordo di tipo =93legale=94, variabile nel tempo e nello =
spazio=20
      (infatti =E8 differente nelle diverse=20
      nazioni).&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Secondo una=20
      convenzione che era accettata fino a non molto tempo fa da molti =
autori,=20
      tre bande nel WB di un donatore di sangue clinicamente sano erano=20
      considerate false reazioni =
positive.&nbsp;</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Secondo=20
      la medesima convenzione, le tre bande dello stesso donatore di =
sangue,=20
      questa volta presentate ad una Societ=E0 di Assicurazione per una =
polizza=20
      sulla vita, sarebbero state considerate vere&nbsp;=20
      positive!&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Il =
gruppo di=20
      ricercatori di Perth che ha analizzato a fondo il significato =
del&nbsp;=20
      WB, ha concluso che le proteine considerate virali non sono =
peculiari del=20
      virus HIV e sono indistinguibili da proteine di origine=20
      cellulare.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>In =
particolare,=20
      secondo lo studio finora non confutato della Eleopulos e coll. , =
la gp 41=20
      corrisponderebbe all=92actina;&nbsp; la p18 e la p24/25 alle due =
subunit=E0=20
      della miosina (la p24 =E8 la banda aspecifica ritrovata con =
maggior=20
      frequenza in soggetti =93non infetti=94); la p32 sarebbe identica =
alla catena=20
      beta dell=92antigene DR della classe di istocompatibilit=E0 II; la =
gp120-160=20
      non sarebbero nient=92altro che oligomeri della=20
      gp41.</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Antigene=20
      p24</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>La=20
      valutazione del test di cattura dell=92antigene p24 =E8 stato =
compreso in USA=20
      tra i test che vengono effettuati ad ogni unit=E0 di sangue (e =
considerato=20
      come =93diretta evidenza del virus =
HIV=94).</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Secondo=20
      Fauci e coll.&nbsp; , viene ritenuto =
che:</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>a) la p24=20
      corrisponde all=92antigene del capside virale (core) che viene =
evidenziato=20
      da un siero contenente i relativi anticorpi monoclonali (anti-p24) =

      associati ad un sistema rivelatore;</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>b) il =
test comunque=20
      non =E8 utile come mezzo di screening primario nello stabilire una =
diagnosi=20
      precoce di infezione da HIV;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>c) =
l=92aumentare del=20
      livello della p24 presumibilmente correla con l=92esplosione nella =

      replicazione virale, rilevabili con altri metodi come la viremia=20
      plasmatica;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>d) il =
livello di=20
      p24 usualmente cade sotto la soglia di determinazione con metodi=20
      convenzionali come l=92anticorpo anti-p24, comincia a formarsi =
durante la=20
      sieroconversione e pu=F2 rimanere in quello stato durante i =
seguenti anni di=20
      infezione asintomatica. Solamente il 20-30% di individui con =
infezione=20
      asintomatica ha livelli rilevabili di p24=20
      sierico.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>Tuttavia le perplessit=E0 sul suo =
reale=20
      significato sono molteplici.&nbsp;</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Dati =
quantitativi=20
      indicano che in pazienti sieropositivi possono essere ritrovati 50 =
pg e=20
      talvolta pi=F9 di proteina del core, la=20
      p24.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>Se un retrovirus pesa 10 -3pg e =
met=E0 del suo=20
      peso =E8 costituita da p24&nbsp;&nbsp; 15, questa quantit=E0 =
corrisponde=20
      allora a circa=20
      =
100.000&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=20
      particelle virali; secondo altri autori e secondo altre premesse=20
      addirittura a 500.000 particelle!&nbsp;</FONT></FONT></FONT>&nbsp; =

      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Dunque,=20
      se tutta questa proteina venisse dai virioni, questi pazienti =
dovrebbero=20
      essere altamente viremici.&nbsp;</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>In =
altre parole vi=20
      dovrebbe essere una corrispondenza diretta tra livelli di p24, =
=93isolamento=20
      virale=94, livelli di =93RNA virale=94 (detta anche =93carica =
virale=94). Invece=20
      cos=EC non =E8. I risultati sono irrimediabilmente differenti da =
quelli che=20
      logicamente sarebbero attesi.&nbsp;</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Per =
esempio, un=20
      lavoro riporta la presenza di antigenemia ma che nessun virus =
pot=E9 essere=20
      isolato da 31 pazienti antigenemici, anche in seguito a =
coltivazione=20
      estesa.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>Osservazioni analoghe sono =
riportate da altri=20
      studi.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Ne =
vengono citati=20
      alcuni:&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>1) =
"in met=E0 dei=20
      casi in cui una persona aveva un test positivo,=20
      =
sus&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbs=
p;&nbsp;&nbsp;=20
      seguentemente ne aveva uno negativo senza assumere alcuna =
medicazione che=20
      avesse potuto alterare i livelli di p24... il test =E8 =
clinicamente erratico=20
      e dovrebbe essere interpretato molto=20
      cautamente=94.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>2) =
l=92antigene p24=20
      non =E8 ritrovato in tutti i soggetti sieropositivi e neppure =
quelli con=20
      AIDS conclamato. In uno studio, la PCR (Polymerase Chain Reaction) =
e la=20
      p24 furono usati per scoprire l=92HIV in pazienti in vari stadi, =
da=20
      asintomatici ad AIDS. La p24 fu trovata nel 24% dei pazienti e =
l=92HIV-RNA=20
      nel 50%.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>3) Oltre il 29% dei riceventi una =
trasfusione=20
      da soggetti sieronegativi, diventa positiva per l=92anticorpo =
anti-p24, pur=20
      =93in assenza di infezione=94.</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>4) La =
non=20
      specificit=E0 del test dell=92antigene p24 =E8 cos=EC ovvia che =
=E8 accettata da=20
      un=92autorit=E0 riconosciuta nel campo, Philip Mortimer -e i suoi =
colleghi-=20
      del Public Health Laboratory Service in Inghilterra: =
=93L=92esperienza ha=20
      dimostrato che n=E9 la coltura virale, n=E9 i test per la p24 sono =
di gran=20
      valore nel test diagnostico. Essi possono essere non sensibili o =
non=20
      specifici=94.</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT=20
      size=3D-1>Conclusione</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT=20
      =
size=3D-1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</F=
ONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>I test=20
      anticorpali (l=92ELISA, il Western Blot ed il test di cattura =
dell=92antigene=20
      p24) per i numerosi motivi sopra esposti, non sono in grado di =
segnalare=20
      con ragionevole sicurezza di trovarsi di fronte ad un=92infezione =
con il=20
      virus HIV e perci=F2 l=92asserzione che il valore predittivo =
positivo del WB=20
      possa essere considerato superiore al 99% non corrisponde alla=20
      realt=E0.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Questi test=20
      rivelano reazioni di una specificit=E0 variabile o meglio =
indeterminata,=20
      tanto da non poter permettere una distinzione tra cross =
reattivit=E0 e=20
      =93infezione da HIV=94.&nbsp;</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT=20
      size=3D-1>L'IDENTIFICAZIONE DIRETTA DEL =
VIRUS</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT=20
      =
size=3D-1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nb=
sp;</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>E=92 comune=20
      convinzione che i test anticorpali siano stati convalidati e in =
qualche=20
      modo verificati da altri in grado di evidenziare il virus stesso, =
test=20
      capaci di identificarlo =
direttamente.&nbsp;</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Tuttavia,=20
      questa determinazione diretta =E8 tale solo all=92apparenza. Si =
limita a=20
      registrare alcuni fenomeni che si crede siano legati in maniera=20
      inequivocabile all=92HIV.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>L=92identificazione=20
      diretta del virus =E8 divisa in due principali categorie&nbsp; =
:&nbsp; la=20
      coltura virale e l=92identificazione diretta degli acidi nucleici =
virali=20
      (Southern Blot, tecniche di amplificazione come PCR, RT PCR, bDNA, =

      NASBA).</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>La coltura=20
      virale</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT=20
      size=3D-1>L=92isolamento virale usualmente coinvolge una =
co-coltura delle=20
      cellule del paziente con cellule di un donatore non infettate che =
sono=20
      state stimolate con fitoemoagglutinina (PHA) per 3=20
      giorni.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Queste co-colture=20
      sono controllate approssimativamente ogni 3 giorni per 28 giorni o =
pi=F9 per=20
      controllare la formazione di sincizi e la presenza di p24 o la=20
      transcriptasi inversa (RT) nel sopranatante della=20
      coltura.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>La =
presenza di=20
      sincizi (a) o dell=92antigene p24 (b) o della RT (c) =E8 =
considerata evidenza=20
      di replicazione virale.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Secondo Gallo ed=20
      altri autori anche il ritrovamento di particelle simil-virali in =
coltura =E8=20
      da ritenersi criterio sufficiente.</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>a)=20
      Comparsa di sincizi</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>La =
comparsa di=20
      sincizi =E8 osservata solamente in una parte delle colture =
considerate=20
      infette, ma le stesse sono presenti anche in linee cellulari =
=93non infette=94=20
      e simili a quelle utilizzate per =
l=92HIV.&nbsp;</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Cos=EC tali=20
      caratteristiche morfologiche cellulari potrebbero essere una=20
      caratteristica delle stesse linee cellulari, del risultato delle=20
      condizioni di coltura o di entrambi questi=20
      fattori.</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>b)=20
      Antigene p24</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>La =
sua mancanza di=20
      specificit=E0 =E8 gi=E0 stata menzionata. Le obiezioni al suo =
utilizzo come test=20
      sul siero del paziente sono valide anche per il suo utilizzo nelle =

      colture.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>In uno studio in cui =E8 stato =
utilizzato questo=20
      metodo di =93isolamento virale=94 (la determinazione della p24 in =
colture con=20
      sangue intero non frazionato), risultati positivi sono stati =
ottenuti in=20
      49 su 60 =93individui=94 (82%) presumibilmente non infetti ma =
sierologicamente=20
      indeterminati e in 5 su 5 donatori di sangue=20
      sieronegativi.</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>c)=20
      Transcriptasi inversa (RT)</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>In =
tutta la ricerca=20
      sull=92HIV, =E8 considerata quale prova di attivit=E0 =
transcriptasica inversa=20
      dell=92HIV la capacit=E0 di copiare lo stampo-innesco =
(template-primer)=20
      A(n).dT&lt;-&gt;15 quando incubato con il sopranatante o il =
materiale=20
      proveniente da co-colture di materiale infetto con il virus =
dell=92AIDS che=20
      si separa ad un livello di 1,16 gm/ml (gradiente di densit=E0 in=20
      sucrosio).</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>In molti casi questa attivit=E0 =
=E8 considerata=20
      sinonimo di =93isolamento =
dell=92HIV=94.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Comunque: (i) Lo=20
      stesso stampo-innesco =E8 anche copiato quando incubato con =
materiale che si=20
      separa nella banda 1,16 mg/ml da colture di cellule leucemiche e=20
      spermatozoi non infetti; ii) lo stampo-innesco A(n).dT&lt;-&gt;15 =
pu=F2=20
      essere trascritto non solo dall=92RT, ma anche da altre polimerasi =
cellulari=20
      del DNA. Tutte le polimerasi cellulari del DNA, alfa, beta e gamma =
possono=20
      copiare l=92A(n).dT. Infatti, nel 1975, una Conferenza =
Internazionale sulle=20
      polimerasi eucariotiche del DNA che comprendeva Baltimore e Gallo, =
defin=EC=20
      la polimerasi gamma del DNA, =93un componente delle cellule =
normali=94, la cui=20
      attivit=E0 pu=F2 essere aumentata da molti fattori compresa la =
stimolazione=20
      del PHA, l=92enzima che =93copia=20
      l=92A(n).dT&lt;-&gt;15</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>con =
alto=20
      rendimento, ma non copia bene il =
DNA=94;</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Da quanto=20
      sopra si deduce che =E8 errato affermare che tale attivit=E0 =
enzimatica sia=20
      peculiare dei retrovirus, tanto meno che sia indice inequivocabile =
della=20
      presenza del retrovirus HIV.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Le =
particelle e le=20
      proteine che si separano a livello della banda 1,16 mg/ml =
potrebbero=20
      riflettere materiale interamente non virale; sicuramente gran =
parte dello=20
      stesso materiale =E8 cellulare e proveniente da colture stimolate =
con PHA=20
      (come vedremo meglio in seguito), per cui l=92attivit=E0 =
transcriptasica=20
      potrebbe derivare da esso.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT=20
      size=3D-1>&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Oggetti con=20
      l=92aspetto retrovirale</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Il =
ritrovamento di=20
      particelle simil-retrovirali in coltura fu considerato da Gallo =
prova di=20
      isolamento dell=92HIV (allora HTLV-III). Tuttavia Gallo, per =
isolare=20
      l=92HTLV-IIIB, us=F2 la linea cellulare H9 (HUT78) e tale linea =
cellulare=20
      rilascia particelle simil-retrovirali anche quando =93non infetta =
con=20
      l=92HIV=94.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>Weiss ha ottenuto il suo =
=93isolato CBL-I=94 dalla=20
      linea cellulare leucemica CEM, una linea cellulare che ospitava =
retrovirus=20
      anche quando non infettati con =
l=92=93HIV=94.</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Nel 1970,=20
      tali particelle erano frequentemente osservate nei tessuti =
leucemici, in=20
      colture di tessuti embrionali e nella maggioranza se non in tutte =
le=20
      placente umane.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Particelle di tipo=20
      C mature od estroflesse appaiono in cellule linfomatose =
metabolicamente=20
      danneggiate ma non infette con =
l=92HIV.&nbsp;</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT=20
      size=3D-1>=93Particelle retrovirali=94 antigenicamente simili =
all=92HIV sono state=20
      trovate in estratti da colture di ghiandole salivari di pazienti =
con la=20
      sindrome di Sjorgen.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Pi=F9 =
importante=20
      ancora, nell=92unico studio di microscopia elettronica, sia in =
vivo che in=20
      vitro in cui furono usati adeguati controlli ed in cui fosse stato =

      effettuato un estensivo esame in cieco dei controlli e del =
materiale del=20
      test, vennero trovate =93particelle virali indistinguibili =
dall=92HIV=94 in una=20
      variet=E0 di linfoadenopatie reattive non associate all=92HIV, =
portando gli=20
      autori a concludere: =93La presenza di tali particelle non =
indicano, di per=20
      s=E9 stesse, un=92infezione con l=92HIV=94 (fig. =
4).</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT=20
      size=3D-1>Conclusione</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>E' =
inevitabile=20
      convenire che n=E9 la presenza di sincizi, n=E9 il riscontro della =
p24, n=E9=20
      l=92attivit=E0 transcriptasica inversa, n=E9 la presenza di =
particelle=20
      similvirali (insomma ciascun elemento che definisce positiva una =
coltura=20
      dell=92HIV) sono =93evidenza di replicazione virale=94, nonostante =
il=20
      significato attribuito sia proprio=20
      questo.&nbsp;</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT=20
      size=3D-1>Identificazione diretta degli acidi=20
      nucleici</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>Per identificazione diretta degli =
acidi=20
      nucleici vengono intese le tecniche del Southern Blot, la PCR, le =
tecniche=20
      di amplificazione quantitative (RT PCR, bDNA, NASBA). =
L=92identificazione si=20
      basa sul riconoscimento e l=92amplificazione di piccole sequenze=20
      nucleotidiche attribuite all=92HIV, non dell=92intero genoma=20
      virale.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Tale =
ricerca viene=20
      effettuata non su colture, ma direttamente sui tessuti (compreso =
il=20
      sangue) del paziente.</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>a) Tecnica=20
      del Southern blot (tecnica che permette di separare ed evidenziare =
acidi=20
      nucleici del tipo ricercato)</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Il =
primo studio fu=20
      condotto da Gallo nel 1984. Usando la tecnica di ibridizzazione =
Southern=20
      Blot (capace teoricamente di identificare una sola cellula infetta =
su 10),=20
      furono esaminati i tessuti di pazienti con AIDS, ma deboli bande =
furono=20
      ritrovate solo in una minoranza di =
essi.</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>b) La PCR=20
      (Reazione polimerasica a catena)</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>La =
sensibilit=E0=20
      della PCR =E8 stimata 92-100% ed =E8 in grado di rilevare una =
cellula=20
      =93infetta=94 su 100.000.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Tuttavia per la sua=20
      alta sensibilit=E0 =E8 altamente soggetta alla falsa positivit=E0 =
a causa di=20
      contaminazioni anche minime o ad altri comuni errori di=20
      laboratorio.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Sequenze=20
      simil-retrovirali sono rinvenibili nel genoma umano in ogni=20
      cellula.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>Gi=E0 nel 1991, Imagawa e Detels =
fecero notare=20
      una potenziale fallacia della PCR. =93La determinazione di parte =
del genoma=20
      - sostenevano - non significa rivelare un virus=20
      completo=94.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>Molto importante =E8 il problema =
dei falsi=20
      positivi. Molti ricercatori contestano l=92affidabilit=E0 della =
PCR a causa=20
      dell=92alto numero di falsi positivi che questo test produrrebbe. =
La PCR non=20
      si =E8 dimostrata riproducibile e falsi positivi e falsi negativi =
furono=20
      osservati in tutti e 7 i laboratori di riferimento coinvolti in un =

      importante studio francese (la concordanza con la sierologia =
variava dal=20
      40% al 100%). In pi=F9, il numero di risultati positivi non =
differiva=20
      significativamente tra i sieronegativi ad alto e a basso=20
      rischio.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Vi =
sono numerose=20
      altre conferme a queste osservazioni:</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>1) =
Uno studio di=20
      efficacia nel valutare le prestazioni dell=92HIV PCR =
nell=92individuare DNA=20
      virale libero da cellule dimostr=F2 =93un disturbante alto tasso =
di positivit=E0=20
      non specifica=94 usando gli inneschi comunemente utilizzati =
(SK38/39, per il=20
      gene della p24 o gag). In realt=E0, simili tassi di positivit=E0 =
vennero=20
      trovati sia per i campioni anticorpo negativi che quelli anticorpo =

      positivi (18% contro il 26%).</FONT></FONT></FONT>&nbsp; <BR><FONT =

      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>2) La =
PCR (DNA-PCR=20
      qualitativa) effettuata su=20
      =
infanti&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=20
      non&nbsp; infetti risult=F2 in diverse occasioni=20
      positiva.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>3) In uno studio di validit=E0 =
della PCR=20
      coordinato dal Gruppo di Lavoro sulla PCR dell=92OMS, il 54% dei =
laboratori=20
      coinvolti avevano problemi con risultati falsamente positivi; 9,3% =
dei=20
      campioni non infetti erano riportati come=20
      positivi.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>4) Gli autori di uno studio =
multicentrico di=20
      valutazione di qualit=E0, affermarono: =93questo studio ha =
dimostrato che i=20
      risultati falsi positivi, nonostante l=92uso di rigorosi algoritmi =

      procedurali, capitano tra gli individui non infetti con frequenza =
tale da=20
      rimanere un serio problema=94.&nbsp;</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Il =
riscontro di un=20
      numero rilevante =93falsi positivi=94 depone per una notevole =
mancanza di=20
      specificit=E0 della PCR.</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>c)=20
      Tecniche quantitative</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Le =
tecniche=20
      =93quantitative=94 sarebbero in grado di calcolare, in modo =
approssimativo, il=20
      numero di virioni per millilitro di plasma utilizzando delle =
opportune=20
      modificazioni di certe tecniche di amplificazione (amplificazione =
del=20
      substrato, come la RT-PCR e la NASBA, o amplificazione del =
segnale, come=20
      la bDNA). Il substrato consiste in =93regioni conservate=94 di un =
gene=20
      presunto virale.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>La =
sensibilit=E0=20
      calcolata =E8: per la RNA RT-PCR di 100 copie of HIV RNA per =
millilitro di=20
      =
plasma&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT></FONT=
>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>; per la=20
      NASBA di 1.000 molecole per millilitro</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>; per la=20
      bDNA (branched DNA) di 10.000 molecole per=20
      millilitro.</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Fino al=20
      1994 si riteneva che l=92HIV fosse presente in piccole quantit=E0 =
nei tessuti=20
      dei soggetti asintomatici e con AIDS e che infettasse poche =
cellule (1=20
      linfocita su 1.000-100.000). Nel 1995 due studi sembrarono =
dimostrare=20
      invece che l=92HIV si replicava molto attivamente fin dalle prime =
fasi=20
      dell=92infezione. Le nuove tecniche sopra menzionate permettevano=20
      apparentemente di rivelare grandi quantit=E0 di virus che prima =
erano=20
      sfuggite all=92osservazione.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Tuttavia se negli=20
      infetti vi fosse una massiccia infezione, come alcuni dei pi=F9 =
conosciuti=20
      esperti sostengono, l=92ibridizzazione con il Southern blot =
sarebbe stata=20
      pi=F9 che sufficiente per rilevarla. Non dimentichiamo che un =
sorprendente=20
      risultato sia con la Southern Blot standard sia con la PCR era =
=93la=20
      scarsit=E0 o l=92apparente assenza del DNA virale in una parte =
considerevole=20
      dei pazienti=94.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Un =
significativo=20
      lapsus freudiano di John Maddox conferma i sospetti: secondo =
Maddox =93sia=20
      Ho che Wei ed i loro colleghi furono in grado di arrivare alle =
loro=20
      allarmanti conclusioni solamente dopo una decade di ricerche =
sull=92HIV=20
      poich=E9 avevano studiato in =E9quipe con dei matematici e =
poich=E9 essi furono=20
      in grado di usare nuove tecniche per rivelare i bassi livelli di =
virus=20
      coinvolto=94!&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Le =
incompatibilit=E0=20
      logiche dei risultati sono macroscopiche ed=20
      evidenti.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>a) Vi =E8 infatti mancanza di =
correlazione tra=20
      p24 e tecniche di amplificazione genica. (Abbiamo gi=E0 menzionato =
il fatto=20
      che la p24 =E8 considerata =93prova diretta di identificazione=20
      dell=92HIV=94).</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Nessuna=20
      correlazione venne trovata tra il livello di p24 e la=20
      RT-PCR.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>La determinazione della carica =
virale era=20
      altamente sensibile quando paragonata alla misurazione della p24 =
(pi=F9 del=20
      95% dei pazienti aveva un carico virale rilevabile mentre solo il =
40 %=20
      aveva una p24 rilevabile), ma nei campioni positivi il livello di =
antigene=20
      e del carico virale aveva una significativit=E0 solamente=20
      borderline.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>b)Nessuna=20
      correlazione venne osservata tra il carico virale=20
      =
quanti&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;=20
      ficato con la NASBA o con Amplicor e la concentrazione con =
l=92antigene=20
      p24.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>Nessuna correlazione fu osservata =
tra la dose=20
      infettiva, la carica virale determinata con NASBA o con =
l=92Amplicor=20
      (RT-PCR).</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>c) Vi =E8 mancanza di correlazione =
anche tra=20
      RT-PCR ed altri test.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>In =
uno studio su=20
      soggetti vaccinati, un gruppo di quattro campioni di siero =
risultarono=20
      positivi alla RT PCR durante un periodo di 11 mesi, incluso un =
risultato=20
      di circa 10&lt;+&gt;4 -105 copie /mL, ed un quinto risultato =
positivo un=20
      anno dopo in un soggetto vaccinato, ma =93non infetto=94. Per =
questo, gli=20
      stessi autori avanzarono =93dubbi riguardanti la specificit=E0 =
della misura=20
      del HIV RNA quale standard aureo per lo screening e la conferma=20
      dell=92infezione=94.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>d) Vi =
=E8 infine=20
      mancanza di correlazione tra =93virus=94 e =93carica=20
      virale=94.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>1) Secondo Piatiak, l=92alto =
livello di =93virus=94=20
      nel plasma era 999 per mille =93non =
coltivabile=94.</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>2) Ho et=20
      al. hanno dimostrato che 10.000 =93virioni=94 plasmatici contati =
con la PCR=20
      ramificata corrispondono a meno di un virus =93infettivo=94 per ml =

      64.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>3) In un pi=F9 recente studio di =
Ho si pu=F2=20
      constatareare che ad una carica di 500.000 unit=E0 (!) =
corrispondevano 0=20
      (zero!) =93virus coltivati=94. Secondo i dati riportati, al =
paziente 105 prima=20
      della cura (con Ritonavir) erano stati riscontrati 643.000 =
=93virioni=94/ml,=20
      il cui numero =E8 stato calcolato con il branched DNA assay ad =
esso=20
      corrispondevano pi=F9 di 1.000 TCID- 50/ml (50% tissue colture =
infectious=20
      doses).&nbsp; Dopo due giorni di terapia e nei giorni seguenti il =
=93virus=20
      coltivabile=94 era 0 (zero). Nel contempo, ai giorni 2, 3 e 4 i =
=93virioni=20
      liberi=94 (ovvero la cosiddetta =93carica virale=94) restava =
superiore a=20
      500.000. Fino al giorno 7 i =93virioni=94 erano ancora superiori a =

      100.000.&nbsp;&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Un =
virione =E8=20
      definito come una particella virale completa costituita =
dall=92acido=20
      nucleico virale, dal capside e dal pericapside (quando presente). =
La=20
      possibile obiezione che un virione difettivo venga =93visto=94 dal =
branched=20
      DNA assay, ma non venga rilevato dai saggi colturali, non risolve =
il=20
      problema della mancata corrispondenza con gli altri test e con=20
      l=92impossibilit=E0 di vedere queste particelle al microscopio =
direttamente=20
      dai tessuti del paziente, senza passaggi=20
      colturali.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Fosse =
stato cos=EC,=20
      Gallo non avrebbe avuto bisogno di ricorrere a frodi, non avrebbe =
avuto=20
      bisogno di tre anni di indefesse ricerche per trovare qualcosa che =
avesse=20
      l=92aspetto di un virus. Ci sarebbe arrivato immediatamente =
assieme ad altri=20
      ricercatori.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Mark =
Craddock,=20
      professore della&nbsp; School of Mathematics and Statistics, The=20
      University of Sydney, Australia ha commentato: =93Cos=92=E8 questa =
grande=20
      viremia di miliardi di particelle di RNA che possono essere visti=20
      solamente con una tecnica non documentata (branched-DNA) o la PCR =
ma non=20
      con test funzionale di =
infettivit=E0=94?</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>&lt;LOR=20
      "IL GENOMA=20
      =
VIRALE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>=
</FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Come gi=E0=20
      detto, le tecniche di amplificazione genica riguardano piccole =
frazioni,=20
      non l=92intero genoma =93virale=94 ed i risultati ottenuti non =
danno la=20
      sicurezza di trovarsi di fronte all=92HIV, tanto pi=F9 che sono =
francamente=20
      discordanti. A questo punto =E8 perci=F2 legittimo domandarsi qual =
=E8 veramente=20
      e com=92=E8 fatto l=92originale genoma =
virale.</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT=20
      size=3D-1>Innanzitutto il gruppo di ricercatori di Perth osserva =
che "se ci=20
      fosse un singolo retrovirus dell=92AIDS, un unico retrovirus, =
allora le=20
      differenze genomiche inferiori all=921% dovrebbero essere la =
regola, non=20
      l=92eccezione.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Per =
esempio, il=20
      vaccino al poliovirus Sabin del tipo 3 differiva dal suo =
progenitore=20
      neurovirulento in solo 10 posizioni nucleotidiche dopo 53 passaggi =
in=20
      vitro e 21 in vivo nei tessuti di scimmie. Nel 1977, l=92influenza =
virale A=20
      H1N1 riapparve nella popolazione umana dopo 27 anni di =
inattivit=E0 con=20
      sequenze principalmente identiche a quelle del virus del=20
      1950".&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Sebbene si sia=20
      usato il modello della quasispecie di Eigen per descrivere il =
genoma dei=20
      virus dell=92RNA, differenze di sequenza anche dell=921% in questi =
genomi=20
      vengono considerate rappresentare =93estrema variabilit=E0=94=94. =
=93Molte forze=20
      selettive possono stabilizzare le popolazioni=20
      virali.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Questi fattori=20
      stabilizzanti possono racchiudere la necessit=E0 della =
conservazione della=20
      struttura e della funzione delle proteine, una struttura =
secondaria=20
      dell=92RNA, siti di glicosilazione e siti di=20
      fosforilazione.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Vediamo ora qual =E8=20
      il quadro offerto dalla ricerca =
sull=92HIV.&nbsp;</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Fu presto=20
      scoperto che =93se si testassero due sieropositivi a caso e si =
analizzasse=20
      il materiale genetico del ceppo di uno e dell=92altro, essi =
differirebbero,=20
      in media, di circa il 13%=94. Inoltre, quello che viene =
considerato il=20
      genotipo dell=92HIV deriva dalle analisi di sequenza di subgenomi =
che=20
      misurano dal 2% al 30% del totale. Il dato sconcertante =E8 che =
tali=20
      =93genomi=94 variano fino al 40%.&nbsp;</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>=93Se =
il 30% del=20
      genoma dell=92HIV varia fino al 40%, di quanto varia il 100% del =
genoma=20
      dell=92HIV?=94 =E8 la legittima domanda della Eleopulos e=20
      coll.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Non =
c=92=E8 accordo tra=20
      gli studiosi sul numero di geni =
dell=92HIV.</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Nel=20
      1988&nbsp; si diceva che il genoma dell=92HIV consisteva in 8 =
geni, nel 1990=20
      in dieci. Nel 1996 Montagnier ha riferito che l=92HIV possiede =
otto geni e=20
      secondo Barr=E9-Sinoussi, l=92HIV ha nove =
geni.</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Nemmeno=20
      il numero dei nucleotidi nel =93genoma dell=92HIV=94 sembra=20
      costante.&nbsp;</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Le quasi=20
      specie</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Poich=E9=20
      venivano riscontrate grandi differenze genomiche&nbsp; - persino =
nello=20
      stesso individuo albergherebbero almeno 10&lt;+&gt;6 -10=20
      8</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>&nbsp;</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>=93varianti=20
      genotipiche=94&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>- per =
tentare di=20
      giustificare tale fenomeno =E8 stato introdotto il concetto di=20
      =93quasi-specie=94.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Prima =
degli anni=20
      =9290, le sequenze dell=92HIV erano classificate come =
europee/statunitensi con=20
      differenze della sequenza del 20-30% tra questi due=20
      gruppi.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Negli =
anni =9290, i=20
      ricercatori dell=92HIV hanno cominciato a dividere il genoma HIV =
nei=20
      sottotipi A, B, C, D, E, etc.&nbsp;</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>La =
base di questo=20
      sistema di classificazione =E8: =93(a) i sottotipi sono =
approssimativamente=20
      equidistanti uno dall=92altro nel gene env;&nbsp; (b) l=92albero =
filogenetico=20
      env =E8 per la gran parte congruente con l=92albero filogenetico =
gag; (c) due=20
      o pi=F9 campioni sono richiesti per definire un sottotipo di=20
      sequenza".&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Tuttavia, =93Sono=20
      sorti dei problemi nel nominare i sottotipi. Un numero piccolo ma =
non=20
      insignificante di sequenze virali sono ibride, ovvero si possono =
riunire,=20
      per esempio un sottotipo di sequenza del gag diventa problematico =
quando=20
      sorgono forme altamente divergenti di un dato sottotipo: tali =
forme sono=20
      talvolta designate come A=92, B=92, F=92, ecc. E=92 sempre pi=F9 =
necessario avere=20
      dei dati che codificano le sequenze sia del gag che dell=92env =
quando si sta=20
      rivendicando una nuova forma o=20
      sottotipo=94.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Verso =
la met=E0 del=20
      1996 erano stati descritti =93almeno dieci=94(A-J) genotipi =
dell=92HIV-I=20
      principali (M) prevalenti e quelli a bassa prevalenza (O) e nuovi =
genotipi=20
      vengono ancora segnalati.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>E=92 =
quindi possibile=20
      descrivere i =93DNA dell=92HIV=94, anche se hanno una variazione =
del 10%, per=20
      non menzionare il 20 o il 30 o il 40%, come una =93popolazione di =
genomi=20
      strettamente imparentati, e riferirsi ad essi come a=20
      quasispecie=94?</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>L=92estrema=20
      variabilit=E0 del genoma dell=92HIV induce a chiedersi che senso =
abbia=20
      riferirsi all=92HIV come ad una entit=E0 dalla precisa fisionomia. =
La=20
      differenza genomica tra uomini di razza diversa si aggira attorno =
all=921=20
      per 1.000, tra uomo ed orango-tan al 2%, ma per trovare una =
differenza del=20
      30%, bisogna confrontare nientemeno che uomo e topo, uomo e asino, =
uomo ed=20
      elefante! Possono correttamente ritenersi il topo e l=92asino e =
l=92elefante=20
      quasi-specie dell=92uomo (fig. 5)?</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>PARTICLE=20
      DETECTION (identificazione di =
particelle)</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>I=20
      Retrovirus sono definiti come particelle con rivestimento di circa =

      100-120nM di diametro con un core che comprende un involucro =
proteico e un=20
      complesso di ribonucleoproteina.&nbsp;</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>I=20
      Retrovirus sono classificati in tre sottofamiglie: Spumavirinae,=20
      Lentivirinae and Oncovirinae.</FONT></FONT></FONT>&nbsp; <BR><FONT =

      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>I =
Retrovirus=20
      appartenenti all=92ultima sottofamiglia sono divisi in particelle =
di tipo A,=20
      B, C e D.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>A quale di questi debba =
appartenere l=92HIV, non=20
      =E8 ben chiaro. Secondo Gallo nel 1984 si trattava di una =
particella di tipo=20
      C, ma nel 1985 ammetteva che poteva essere anche del tipo=20
      D.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>Montagnier e colleghi riportarono =
inizialmente=20
      che era una particella di tipo C, quindi di tipo D, e quindi un=20
      lentivirus, ovvero di un=92altra sottofamiglia. Secondo Munn ed =
altri il=20
      virus dell=92AIDS presenta caratteristiche del tipo C, del tipo D =
e dei=20
      lentivirus. Fauci ed altri descrissero l=92HIV in colture=20
      monocitarie/macrofagiche come particelle retrovirali con =
caratteristiche=20
      di tipo A.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>L=92HIV pare assumere =
un=92identit=E0 cos=EC=20
      imprecisa, cangiante, da aggiungere ulteriori motivi di=20
      perplessit=E0.</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT=20
      =
size=3D-1>FOTOGRAFIE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Diversi=20
      ricercatori nel campo dell=92AIDS hanno presentato=20
      =
foto&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nb=
sp;&nbsp;&nbsp;=20
      grafie del virus HIV, ma quelle che si vedono sono solo particelle =

      similvirali indistinguibili da microvescicole cellulari normali. =
Queste=20
      particelle, in contrasto con i virus, sono molto instabili quando =
rimosse=20
      dal loro contesto, ed =E8 difficile isolarle e fotografarle in uno =
stato di=20
      vero isolamento.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Viceversa i virus=20
      sono stabili perch=E9 essi devono lasciare di nuovo le cellule o =
gli=20
      organismi parassitati. L=92uso di tecniche di centrifugazione non=20
      costituisce un problema per separare i virus dai vari contaminanti =
ed=20
      ottenere cos=EC il loro isolamento - quindi fotografarli, quindi =
evidenziare=20
      le loro proteine ed i loro costituenti genetici in modo=20
      diretto.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>I virus veri sono cos=EC stabili =
che =E8 facile=20
      fotografarli direttamente come particelle tridimensionali nel =
microscopio=20
      elettronico a scansione senza che sia necessario fissarli prima=20
      chimicamente.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>All=92opposto, le=20
      microvescicole sono cos=EC instabili che esse possono essere =
fotografate=20
      solo con un microscopio elettronico a=20
      =
trasmis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;=20
      sione, che richiede che siano fissate chimicamente in sezioni =
molto=20
      sottili. Tutto ci=F2 che =E8 stato mostrato al mondo intero come =
micrografie=20
      dell=92HIV sono sezioni ultrasottili che includono particelle=20
      indistinguibili da quelle cellulari (vedi figg.=20
      6-8).</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT=20
      =
size=3D-1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT></FONT>&nbsp; =

      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>LA PROVA=20
      DELL'(IN)ESISTENZA=20
      =
DELL'HIV&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Una=20
      importantissima conferma alle argomentate critiche dei ricercatori =
di=20
      Perth =E8 arrivata nel marzo del 1997: due gruppi, uno =
franco/tedesco e uno=20
      del National Cancer Institute statunitense, hanno finalmente =
pubblicato le=20
      fotografie dei gradienti di densit=E0 in cui doveva essere =
presente il virus=20
      HIV isolato, puro (fig. 9).&nbsp;</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Questo dato avrebbe=20
      dovuto essere disponibile fin dal momento della scoperta del virus =

      (1983-84), ma nessuno prima l=92aveva fatto. Ed il motivo pi=F9 =
verosimile =E8=20
      che manca totalmente la corrispondenza tra quello che era =
riscontrato e=20
      quello che avrebbe dovuto esserci.</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Nello =
studio=20
      franco/tedesco le fotografie provengono dalla banda 1,16=20
      gm/ml.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>E=92 =
impossibile dire=20
      da quale densit=E0 provengono le fotografie dello studio =
americano, ma=20
      presumibilmente =E8 anch=92essa corrispondente a 1,16 gm/ml (dove =
si ritrovano=20
      i retrovirus).</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>La =
Eleopulos et al.=20
      rilevano che =93gli autori di entrambe le pubblicazioni ammettono =
che le=20
      particelle che sono presenti nel materiale della banda di =
gradiente e che=20
      sono definiti HIV rappresentano solo una frazione molto =
piccola&nbsp; del=20
      materiale totale. Gelderblom et al. affermano che il materiale =
contiene un=20
      eccesso di vescicole cellulari con una dimensione di 50-500 nM, =
come=20
      opposte ad una popolazione minore di particelle virali ...&nbsp; =
le=20
      vescicole cellulari sembrano essere il maggiore contaminante delle =

      preparazioni di HIV arricchite dalla centrifugazione in gradiente =
di=20
      sucrosio=94.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>=93Riguardo il piccolo numero di =
particelle=20
      considerate HIV non c=92=E8 nessuna prova che lo siano=20
      veramente.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Al=20
      contrario:&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>(a) =
le particelle=20
      non sembrano avere estroflessioni superficiali. In altri lavori =
pubblicati=20
      da diversi ricercatori, incluso Gelderblom e i suoi colleghi viene =

      espressamente notata l=92assenza di queste=20
      proiezioni;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>(b) =
le particelle=20
      riferite come HIV non sono sferiche ed hanno diametri superiori a=20
      100-120nM. Nella fotografia al microscopio elettronico di =
Gluschankof e=20
      coll., ci sono frecce che puntano a 5 =93virioni=94 senza =
proiezioni=20
      superficiali, le cui dimensioni sono: 121 X 145; 121 X&nbsp; 169; =
121 X=20
      145, 121 X 145 e 133 X 145 nM.</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Nello =
studio di=20
      Bess e coll. sono indicate un totale di sei particelle di HIV, =
anch=92esse=20
      prive di proiezioni di superficie, le cui dimensioni sono 160 X =
240; 200 X=20
      240; 280 X 280; 208 X 250; 167 X 250 and 250 X 292 and=20
      nM.=94</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT size=3D-1>=93In realt=E0, essi sostengono =
che quelle sono=20
      particelle dell=92HIV, ma senza fornire nessuna=20
      prova.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Nel =
materiale di=20
      quella banda di densit=E0 dovrebbero esserci moltissime particelle =
virali,=20
      invece ne sono indicate solo alcune, in mezzo a molte=20
      impurit=E0.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Queste particelle=20
      hanno solo una vaga rassomiglianza con quelle che dovrebbero =
essere delle=20
      particelle retrovirali=94.</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>=93Il =
punto=20
      fondamentale =E8 che ogni genuina particella retrovirale dovrebbe =
contenere=20
      la stessa quantit=E0 di RNA e proteine, n=E9 pi=F9 n=E9 meno. =
Questo significa che=20
      se noi consideriamo i diametri delle particelle indicate nei due =
studi=20
      citati, essi sono da 1,14 a 1,96 volte pi=F9 grandi del massimo =
previsto per=20
      il normale HIV. Traducendo questo in volumi, e confrontando con =
una=20
      particella con diametro di 120nM, le particelle franco/tedesche =
hanno un=20
      volume 50% maggiore, quelle statunitensi uno 750% maggiore=94, =
ovvero=20
      incompatibile con la difinizione di =
retrovirus!</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Anche se=20
      non =E8 ammesso dagli autori, i dati dei due lavori citati =
contribuiscono a=20
      dimostrare che l=E0 dove doveva essere presente l=92HIV puro, =
dell=92HIV non c=92=E8=20
      traccia.</FONT></FONT></FONT>&nbsp; <BR><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000000><FONT=20
      =
size=3D-1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT></FONT>&nbsp; =

      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT=20
      size=3D-1>CONCLUSIONI</FONT></FONT></FONT>&nbsp;=20
      <P><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Nessuno=20
      dei test esaminati appare sufficientemente sicuro per individuare=20
      un=92infezione da HIV. Paradossalmente neppure la =
=93determinazione diretta=20
      del virus=94 =E8 in grado di rispondere allo stesso quesito, tanto =
=E8 vero che=20
      vi =E8 una inconciliabile discordanza dei risultati ottenuti con =
le varie=20
      metodiche che ne vengono perci=F2=20
      invalidati.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>In =
pi=F9 non risulta=20
      dimostrata l=92esistenza di un=92entit=E0 che possa =
ragionevolmente chiamarsi=20
      =93il virus HIV=94, sia nelle sue componenti proteiche, sia nel =
genoma, sia=20
      come particella fisica. Il vero significato dei test =E8 meglio =
compreso se=20
      viene esaminata la loro origine.</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Per =
provare=20
      l=92esistenza di un nuovo virus sia il gruppo di Montagnier nel =
1983 che=20
      quello di Gallo nel 1984 separarono il sopranatante di colture =
ritenute=20
      infette in gradienti di densit=E0. Considerarono - erroneamente - =
che il=20
      materiale che si separava al livello di 1,16 mg/ml fosse =
costituito da=20
      =93pure particelle di HIV=94.&nbsp;</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Le =
proteine=20
      presenti in questa banda e che sono reattive con i sieri di =
pazienti con=20
      AIDS (ma non solo con i loro sieri) furono considerate proteine =
dell=92HIV.=20
      Ugualmente, una particolare frazione di RNA ritrovata nella =
medesima banda=20
      di separazione fu considerata il genoma del nuovo virus. Da =
allora, alcune=20
      di queste proteine sono usate per ricavare i reattivi per alcuni =
test o=20
      come immunogeni per produrre negli animali di laboratorio gli =
anticorpi=20
      utilizzati per altri test (un procedimento simile venne seguito =
con certi=20
      frammenti di RNA). A questo punto la spiegazione degli esperimenti =
di=20
      Gallo effettuati nel 1984 appare pi=F9 chiara: utilizz=F2 un =
miscuglio di=20
      proteine (ritenute virali ma in realt=E0 cellulari) per =
immunizzare i=20
      conigli ed ottenere cos=EC un siero che ovviamente reagiva con le =
stesse=20
      proteine presenti nelle colture da cui=20
      proveniva.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>In =
altre parole=20
      Gallo ha creduto di dimostrare la sua ipotesi (l=92esistenza del =
virus) con=20
      altre ipotesi rivelatesi errate (che l=92attivit=E0 =
transcriptasica inversa,=20
      la presenza di particelle similvirali, gli anticorpi in quel modo =
trovati=20
      fossero specifici per il virus).&nbsp;</FONT></FONT></FONT>&nbsp;=20
      <BR><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Cos=EC sono=20
      nati i test che ancora oggi vengono utilizzati e perfezionati per =
porre=20
      una diagnosi cos=EC impegnativa.</FONT></FONT></FONT>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>Una =
importante=20
      prova della correttezza di questa interpretazione dei fatti sta =
nei=20
      risultati che vennero ottenuti su topi e scimmie nel 1991. In =
questi=20
      studi, allo scopo di valutare un potenziale vaccino, alcuni =
animali di=20
      laboratorio vennero iniettati con componenti cellulari da colture =
non=20
      infette con l=92HIV: i risultati furono simili a quelli ottenuti =
con il=20
      =93vaccino vero e proprio=94 (cio=E9 con =93virus da colture=20
      infette=94).&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Nessuna differenza=20
      significativa venne rilevata, tanto che il commento perfettamente=20
      appropriato ed ancora attuale di John Maddox fu: =93la ricerca =
sull=92AIDS si=20
      =E8 capovolta=94.&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>In =
altre parole,=20
      per aver ottenuto quei risultati non c=92era alcun bisogno di =
ipotizzare la=20
      presenza di un virus HIV.</FONT></FONT></FONT>&nbsp;=20
      <P><B><I><FONT face=3DArial,Helvetica><FONT color=3D#000000><FONT=20
      size=3D-1>Fabio Franchi</FONT></FONT></FONT>&nbsp;</I></B>&nbsp; =
<BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Specialista in=20
      Igiene,&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT =
size=3D-1>Medicina=20
      Preventiva&nbsp;</FONT></FONT></FONT>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT size=3D-1>e in =
Malattie=20
      Infettive</FONT></FONT></FONT>&nbsp; <BR><B><FONT=20
      face=3DArial,Helvetica><FONT color=3D#000000><FONT=20
      size=3D-1>Trieste</FONT></FONT></FONT></B></P></TD>
    <TD vAlign=3Dtop width=3D"10%" align=3Dleft>
      <CENTER>&nbsp;</CENTER>
      <CENTER>
      <TABLE border=3D1 width=3D150 bgColor=3D#333333 cols=3D1>
        <TBODY>
        <TR>
          <TD>
            <CENTER>&nbsp;</CENTER>
            <CENTER><A =
href=3D"http://www.cesil.com/0898/frhimg1.htm"><IMG=20
            border=3D1 align=3DABSCENTER=20
            src=3D"http://www.cesil.com/0898/fraimg1p.jpg" width=3D100=20
            height=3D64></A></CENTER>
            <CENTER><FONT face=3DArial,Helvetica><FONT =
color=3D#ffffff><FONT=20
            size=3D-1>Fig.=20
      1</FONT></FONT></FONT></CENTER></TD></TR></TBODY></TABLE></CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>
      <TABLE border=3D1 width=3D150 bgColor=3D#333333 cols=3D1>
        <TBODY>
        <TR>
          <TD>
            <CENTER><A =
href=3D"http://www.cesil.com/0898/frhimg2.htm"><IMG=20
            border=3D1 align=3DABSCENTER=20
            src=3D"http://www.cesil.com/0898/fraimg2p.jpg" width=3D100=20
            height=3D65></A></CENTER>
            <CENTER><FONT face=3DArial,Helvetica><FONT =
color=3D#ffffff><FONT=20
            size=3D-1>Fig.=20
      2</FONT></FONT></FONT></CENTER></TD></TR></TBODY></TABLE></CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>
      <TABLE border=3D1 width=3D150 bgColor=3D#333333 cols=3D1>
        <TBODY>
        <TR>
          <TD>
            <CENTER><A =
href=3D"http://www.cesil.com/0898/frhimg3.htm"><IMG=20
            border=3D1 align=3DABSCENTER=20
            src=3D"http://www.cesil.com/0898/fraimg3p.jpg" width=3D100=20
            height=3D77></A></CENTER>
            <CENTER><FONT face=3DArial,Helvetica><FONT =
color=3D#ffffff><FONT=20
            size=3D-1>Fig.=20
      3</FONT></FONT></FONT></CENTER></TD></TR></TBODY></TABLE></CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>
      <TABLE border=3D1 width=3D150 bgColor=3D#333333 cols=3D1>
        <TBODY>
        <TR>
          <TD>
            <CENTER><A =
href=3D"http://www.cesil.com/0898/frhimg4.htm"><IMG=20
            border=3D1 align=3DABSCENTER=20
            src=3D"http://www.cesil.com/0898/fraimg4p.jpg" width=3D100=20
            height=3D59></A></CENTER>
            <CENTER><FONT face=3DArial,Helvetica><FONT =
color=3D#ffffff><FONT=20
            size=3D-1>Fig.=20
      4</FONT></FONT></FONT></CENTER></TD></TR></TBODY></TABLE></CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>&nbsp;</CENTER>
      <CENTER>
      <TABLE border=3D1 width=3D150 bgColor=3D#333333 cols=3D1>
        <TBODY>
        <TR>
          <TD>
            <CENTER><A =
href=3D"http://www.cesil.com/0898/frhimg5.htm"><IMG=20
            border=3D1 align=3DABSCENTER=20
            src=3D"http://www.cesil.com/0898/fraimg5p.jpg" width=3D80=20
            height=3D80></A></CENTER>
            <CENTER><FONT face=3DArial,Helvetica><FONT =
color=3D#ffffff><FONT=20
            size=3D-1>Fig.=20
      5</FONT></FONT></FONT></CENTER></TD></TR></TBODY></TABLE></CENTER>
      =
<CENTER>&nbsp;</CENTER></TD></TR></TBODY></TABLE></CENTER>&nbsp;<FONT=20
face=3DArial,Helvetica><FONT size=3D-1>&nbsp;</FONT></FONT>=20
<TABLE border=3D0 cellPadding=3D3 width=3D700 cols=3D2>
  <TBODY>
  <TR>
    <TD vAlign=3Dtop><FONT size=3D-1><B><I><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#006600>&nbsp;Leadership =
Medica</FONT></FONT></I></B><SUP><FONT=20
      face=3DArial>=AE</FONT></SUP>&nbsp;</FONT>&nbsp; <BR><FONT =
size=3D-1>&nbsp;<A=20
      href=3D"mailto:ldmedica@cesil.com"><IMG border=3D0 =
align=3DABSCENTER=20
      src=3D"http://www.cesil.com/0898/mail.gif" width=3D14 =
height=3D11></A><I><FONT=20
      face=3DArial,Helvetica> Mensile di scienza&nbsp; medica e=20
      attualita`</FONT></I>&nbsp;</FONT>&nbsp; <BR><FONT=20
      face=3D"arial, helvetica"><FONT size=3D-1>&nbsp;</FONT><FONT =
size=3D-2>Copyright=20
      1997=A9 All Rights Reserved</FONT></FONT><FONT =
size=3D-2>&nbsp;</FONT></TD>
    <TD>
      <DIV align=3Dright><A href=3D"http://www.cesil.com/index.htm"><IMG =
border=3D0=20
      src=3D"http://www.cesil.com/0898/homeld.jpg" width=3D50=20
  height=3D50></A></DIV></TD></TR></TBODY></TABLE>&nbsp;<A=20
href=3D"http://www.cesil.com/0898/info08.htm"><IMG border=3D0 =
align=3DABSCENTER=20
src=3D"http://www.cesil.com/0898/bottpiui.gif" width=3D120 =
height=3D54></A>=20
<TABLE border=3D0 cellPadding=3D3 width=3D700 cols=3D2>
  <TBODY>
  <TR>
    <TD vAlign=3Dtop><FONT size=3D-2>&nbsp;This pages are maintened =
by</FONT><FONT=20
      size=3D-1>&nbsp;</FONT>&nbsp; <BR><B><I><FONT =
face=3DArial,Helvetica><FONT=20
      color=3D#000099><FONT size=3D-1><A =
href=3D"http://www.coloseum.com/gtmgraph">GTM=20
      Grafica</A></FONT></FONT></FONT></I></B>&nbsp; <BR><FONT=20
      face=3DArial,Helvetica><FONT size=3D-2>Service &amp;=20
      Network</FONT></FONT>&nbsp; <BR><A=20
      href=3D"mailto:gtmgraph@coloseum.com"><IMG border=3D0=20
      src=3D"http://www.cesil.com/0898/mail.gif" width=3D14 =
height=3D11></A><FONT=20
      face=3DArial><FONT size=3D-2> =
gtmgraph@coloseum.com</FONT></FONT></TD>
    <TD vAlign=3Dtop>
      <DIV align=3Dright>&nbsp;</DIV></TD></TR></TBODY></TABLE>&nbsp; =
</BODY></HTML>

------=_NextPart_000_0000_01CAE65D.A1CA30D0
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.cesil.com/0898/migltin1.gif
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------=_NextPart_000_0000_01CAE65D.A1CA30D0
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.cesil.com/0898/tosctin2.gif

R0lGODdhJgIUAJEAAP////sAAQAAAAAAACwAAAAAJgIUAAACeoyPqcvtD6OctNqLs968+w+G4kiW
5omm6sq27gvH8kzX9o3n+s73/g8MCofEovGITCqXzKbzCY1Kp9Sq9YrNarfcrvcLDovH5LL5jE6r
1+y2+w2Py+f0uv2Oz+v3/L7/DxgoOEhYaHiImKi4yNjo+AgZKTlJWWl56VcAADs=

------=_NextPart_000_0000_01CAE65D.A1CA30D0
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.cesil.com/0898/frahtes1.jpg
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------=_NextPart_000_0000_01CAE65D.A1CA30D0
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.cesil.com/0898/frahtes2.jpg
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------=_NextPart_000_0000_01CAE65D.A1CA30D0
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.cesil.com/0898/ficapalb.jpg
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------=_NextPart_000_0000_01CAE65D.A1CA30D0
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.cesil.com/0898/usa.gif
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------=_NextPart_000_0000_01CAE65D.A1CA30D0
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.cesil.com/0898/fraimg1p.jpg
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------=_NextPart_000_0000_01CAE65D.A1CA30D0
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.cesil.com/0898/fraimg2p.jpg
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------=_NextPart_000_0000_01CAE65D.A1CA30D0
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.cesil.com/0898/fraimg3p.jpg
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------=_NextPart_000_0000_01CAE65D.A1CA30D0
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.cesil.com/0898/fraimg4p.jpg
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------=_NextPart_000_0000_01CAE65D.A1CA30D0
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.cesil.com/0898/fraimg5p.jpg
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------=_NextPart_000_0000_01CAE65D.A1CA30D0
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.cesil.com/0898/mail.gif

R0lGODdhDgALAKIAAP//////AMbGxoSEhISEAAAAAAAAAAAAACwAAAAADgALAAADNDi6vDUAhChp
KK/YXcgTxRSJ3fAEYBV1ggkB3si2JyF4mG27tnATvZvLRyz6XI2kCcNsOhMAOw==

------=_NextPart_000_0000_01CAE65D.A1CA30D0
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.cesil.com/0898/homeld.jpg
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------=_NextPart_000_0000_01CAE65D.A1CA30D0
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.cesil.com/0898/bottpiui.gif
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------=_NextPart_000_0000_01CAE65D.A1CA30D0
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.cesil.com/0898/ficasfon.jpg
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=

------=_NextPart_000_0000_01CAE65D.A1CA30D0--

